Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) plans to report its fiscal Q4 and full-year financial results for the period ending September 30, 2022, on November 21, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide business updates, including developments in its research and development pipeline targeting respiratory syncytial virus, SARS-CoV-2, and hepatitis B virus. Funding for these activities is supported by royalties from its collaboration with AbbVie on hepatitis C virus treatments.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 after the U.S. market closes on November 21, 2022. Enanta management will then host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information
The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website https://ir.enanta.com/events-presentations or by clicking here. To participate by phone, please register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Enanta’s website following the event.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005150/en/

Media and Investor

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What financial results will Enanta Pharmaceuticals report on November 21, 2022?

Enanta Pharmaceuticals will report its fiscal Q4 and full-year financial results for the year ending September 30, 2022.

What time is the Enanta Pharmaceuticals conference call on November 21, 2022?

The conference call will take place at 4:30 p.m. ET.

Where can I access the Enanta Pharmaceuticals webcast for its financial results?

The live webcast can be accessed through the 'Events & Presentations' section of Enanta's investor website.

What disease targets is Enanta Pharmaceuticals focusing on?

Enanta Pharmaceuticals is targeting respiratory syncytial virus, SARS-CoV-2, and hepatitis B virus in its research and development programs.